HIGH GRADE GLIOMAS
DIAGNOSIS
MANAGEMENT AND CONTROVERSIES
INTRODUCTION

- High-grade gliomas (HGGs) represent a heterogeneous group of tumors and account for most primary brain tumors.
- Despite aggressive therapies, they are invariably associated with poor patient outcome.
- Include -
  - 1) anaplastic (World Health Organization [WHO] grade III) histologies of
    - astrocytomas,
    - oligodendrogliomas
    - ependymomas
  - 2) WHO grade IV glioblastoma multiforme (GBM).
Glioma Grading

Astrocytoma  ⇐ mixed ⇒ Oligodendroglioma

Median survival (range)

- **Grade II: 5 yr (3-10y)**
  - Nuclear atypia

- **Grade III: 3 yr**
  - Nuclear atypia + mitosis

- **Grade IV: 1 yr**
  - Nuclear atypia + mitosis + either endothelial proliferation and/or necrosis

- **Grade II: 15 yr (8-20y)**

- **Grade III: 3 yr**

- **Grade IV: 1 yr**

  - Nuclear atypia + mitosis + either endothelial proliferation and/or necrosis

- The World Health Organization (WHO) scheme is based on the appearance of certain characteristics: atypia, mitoses, endothelial proliferation, and necrosis
**Epidemiology**

- Annual incidence approximately 5 cases per 100,000.
- Glioblastomas account for approximately 60 to 70% of malignant gliomas,
  - anaplastic astrocytomas for 10 to 15%,
  - anaplastic oligodendrogliomas and anaplastic oligoastrocytomas for 10%;
  - anaplastic ependymomas and anaplastic gangliogliomas account for the rest.

INDIA

- Among series of 500 patients with glioma (AIIMS)
  - 222 (44%) patient had high grade glioma.
  - 73.6% were male.

- Banerji AK, epidemiology of CNS tumours (1974-78) neuro oncology 1981 p 43
- Tandon PN, supratentorial gliomas neurol india, 42;131,1994
The median age of patients at the time of diagnosis is

- 64 years in the case of glioblastomas
- 45 years in the case of anaplastic gliomas.

MOLECULAR PATHOGENESIS

- Glioblastomas - two main subtypes
- on the basis of biologic and genetic differences.
  Primary Glioblastomas
  - occur in patients older than 50 years
  - characterized by EGFR amplification and mutations, loss of heterozygosity of chr 10q and p16 deletion.

SECONDARY GLIOBLASTOMAS

- younger patients as low-grade or anaplastic astrocytomas transform over a period of several years into glioblastoma.
- less common than primary glioblastomas,
- characterized by mutations in the p53 tumor suppressor gene, over expression of the platelet derived growth factor receptor (PDGFR), abnormalities in the p16 and retinoblastoma (Rb) pathways, and loss of heterozygosity of chromosome 10q.

Despite their genetic differences primary and secondary glioblastomas are morphologically indistinguishable and respond similarly to conventional therapy,
but they may respond differently to targeted molecular therapies.

**High-grade oligodendrogliomas**

Characterized by the loss of chromosomes 1p and 19q (in 50 to 90% of patients).
DEREGULATED GROWTH FACTOR SIGNALING

- Most common defects in growth-factor signaling involve EGFR and PDGFR.
- EGFR gene amplification is one of the most common genetic events in glioblastomas.
- The most common EGFR mutant is the constitutively active EGFRvIII.
- Seen almost exclusively in primary glioblastomas and is seen in approximately 40 to 50%.
Molecular Pathways in Gliomas

Differentiated astrocytes or precursor cells

- p53 mutation (>65 percent)
- PDGF-A, PDGFR-α
  - overexpression (<-60 percent)

  Low grade astrocytoma

  - LOH 19q (<-50 percent)
  - RB alteration (<-25 percent)

  Anaplastic astrocytoma

  - LOH 10q
  - PTEN mutation (<5 percent)
  - DCC loss of expression (<-50 percent)
  - PDGFR-α amplification (<-10 percent)

  Secondary glioblastoma

  - EGFR
    - amplification (<-40 percent)
    - overexpression (<-60 percent)

  Low grade astrocytoma

  - MDM2
    - amplification (<-10 percent)
    - overexpression (<-50 percent)

  - p16 deletion (30-40 percent)

  Anaplastic astrocytoma

  - LOH 10p and 10q
  - PTEN mutation (<-30 percent)

  RB alteration

  Secondary glioblastoma

  - Primary glioblastoma de novo

LOH: Loss of heterozygosity
RB: Retinoblastoma gene
PDGF: Platelet-derived growth factor
PDGFR: Platelet-derived growth factor receptor
DCC: Deleted in Colon Cancer gene
DIAGNOSIS

Clinical
Radiographical
Pathologic
CLINICAL PRESENTATION
(VARIES DEPENDING UPON SIZE AND LOCATION OF TUMOR)

Most common symptoms:
  Headache (80%)
  Seizure (30%)
  Focal neurologic deficits
  Change in mental status

Time from initial symptoms to diagnosis usually < 6 months (70% of patients)
RADIOLOGY

- CT HEAD
- Features - nonspecific.
- Overlap of imaging features between low- and high-grade gliomas (HGG).
“Density”

- Variable
- Usually isodense to moderately hyperdense to gray matter (the isocenter of the mass may appear denser because of the surrounding vasogenic edema).
- Small or atypically hypo dense mass may not be visible on non-enhanced CT study, masked by the presence of the surrounding, low-density, vasogenic edema-infarct
- **Hemorrhage**
  - depicted as an area of high density
  - commonly seen in advanced grade gliomas
  - (World Health Organization [WHO] grade III–IV), particularly glioblastomas
  - not a pathognomonic feature;
**CALCIFICATIONS**

- Low-grade gliomas are more likely to be calcified
- Small percentage of HGG also shows calcifications

- Prognostic significance of CT contrast enhancement
VASOGENIC EDEMA

- indirect indicator of the aggressive growth of a brain tumor
- responsible for the secondary mass effect.
- Focal region of vasogenic edema may be the only finding on unenhanced CT in cases of HGG or intracranial metastases.
- White matter edema produced by HGG, particularly GBM, can be quite extensive and actually represents a tumor plus edema

**Contrast Enhancement**

- Contrast enhancement high sensitivity and specificity for HGG (about 87 and 79%, respectively).
- 20% of low-grade gliomas.
- Likewise, a substantial number of nonenhancing brain tumors can turn out to be HGG, particularly anaplastic astrocytomases.
- Enhancement on CT imaging—negative prognostic factor, irrespective of the glioma grade.
- Contrast enhanced area (CEA) of >4 cm and heterogenous enhancement as negative prognostic factors.
- CEA <4cm and homogenous enhancement indicates better prognosis.

ANAPLASTIC ASTROCYTOMAS

- Because of their infiltrative growth, indistinct margins - ill-defined, inhomogeneous lesions on CT.
- High cellularity - the attenuation usually ranges from intermediate to high in relation to the normal brain.
- Cystic change or necrosis and hemorrhage are uncommon.
- AA more homogenous compared with GBM.
- Calcification is rare.

- Post-contrast CT studies usually show limited to moderate patchy/heterogenous enhancement.
**Glioblastoma Multiforme**

- NCCT - mixed density complex mass with disproportionate surrounding vasogenic edema, usually involves corpus callosum.
- Marked heterogeneity - necrosis and hemorrhage.
- Central necrosis is an imaging hallmark of GBM.
- Hemorrhage is seen in about 20% of GBM.
- *Vasogenic edema is a prominent imaging feature of GBM and commonly* extends along the white matter tracts.
- GBM typically shows heterogeneous rim enhancement with irregular thick and nodular margins.
ANAPLASTIC OLIGODENDROGLIOMA /OLIGOASTROCYTOMA

- Involve cortex and sub cortical white matter.
- Typical finding is a well defined mixed density superficial frontal lobe mass with calcifications.
- Nodular, clumped, or even gyriform.
- Involved cortex is expanded, cystic degeneration is common, and hemorrhage or necrosis may also be seen.
- Lesions may expand, remodel, or erode the calvarium.
**Gliosarcoma**

- Subtype of GBM in which a sarcomatous component is there.
- Typically present along the periphery, abutting the dura.
- Sharply defined, round or lobulated, hyperdense solid mass
- Homogeneous contrast enhancement and peri-tumoral edema.
- Tendency to invade adjacent dural reflections.
- Mimics meningioma; both in imaging and surgery.
- More heterogenous, have a smaller dural based attachment
- Significant amount of parenchymal edema.
ADVANTAGES OF CT

- Superior in detecting calcification, hemorrhage and in evaluating bone changes related to tumors.
- Pacemakers or metallic devices as well as critically ill or unstable patient.
- Assessment of immediate post-operative complications.
MAGNETIC RESONANCE IMAGING

- Infiltrative parenchymal masses.
- Hyperintense on FLAIR and T2-weighted images.
- Hypointense on unenhanced T1-weighted images.
- May or may not extend into the corpus callosum.
- Surrounded by extensive vasogenic edema.
- Prominently enhance following gadolinium administration.
Anaplastic astrocytoma: (A) Axial T2-weighted image demonstrating large infiltrative mass in the left frontal lobe that is heterogeneously hyperintense, presumably representing the heterogeneity of the histology. (B) Large irregular nodular foci and small ill-defined patchy foci of enhancement are detected in the inferior left frontal lobe on this gadolinium-enhanced T1-weighted spin echo images.
Glioblastoma multiforme: **(A) Axial TSE T2 image demonstrates a large heterogeneous soft tissue mass that extends to either side of midline. There is extensive confluent surrounding hyperintensity in the white matter of both cerebral hemispheres that likely represents a combination of edema and infiltrative neoplasm. (B) The mass clearly involves both mesial frontal lobes and the patchy hyperintensity within the mesial left frontal lobe suggests recent hemorrhage.**
Following gadolinium administration, there is prominent, heterogeneous and multiloculated enhancement that involves both frontal lobes and the intervening body of the corpus callosum, typical for a glioblastoma.
TREATMENT

- Surgery
- Radiation
- Chemotherapy
Summary of Current Treatments for Malignant Gliomas.

Type of Tumor Therapy

Newly diagnosed tumors Glioblastomas (WHO grade IV).

Maximal surgical resection, plus radiotherapy, plus concomitant and adjuvant TMZ or carmustine wafers (Gliadel).

Anaplastic astrocytomas (WHO grade III)

Maximal surgical resection, with the following options after surgery (no accepted standard treatment): radiotherapy, plus concomitant and adjuvant TMZ or adjuvant TMZ alone.

Data are from Sathornsumetee et al.,3 Furnari et al.,18 Chi and Wen,20 and Sathornsumetee et al.21

- PCV denotes procarbazine, lomustine (CCNU), and vincristine, and TMZ temozolomide
- Anaplastic oligodendrogliomas and anaplastic oligoastrocytomas (WHO grade III)

Maximal surgical resection, with the following options after surgery (no accepted standard treatment): radiotherapy alone, TMZ or PCV with or without radiotherapy afterward, radiotherapy plus concomitant and adjuvant TMZ, or radiotherapy plus adjuvant TMZ.

- Recurrent tumors

Reoperation in selected patients, carmustine wafers (Gliadel), conventional chemotherapy (e.g., lomustine, carmustine, PCV, carboplatin, irinotecan, etoposide), bevacizumab plus irinotecan, experimental therapies.
SURGICAL RESECTION

- Incurable secondary to the infiltrative nature
- Rationale behind resection:
  - to obtain definitive histologic diagnosis.
  - to palliate symptoms from local tumor effect.
  - to potentially provide better tumor control with radiation/chemotherapy.
  - to provide tissue for molecular/genetic analysis.
  - to provide improved survival.

prognostication and research.
Controversy exists behind the correlation between the extent of resection and survival.

Goal is to remove as much tumor without causing neurologic dysfunction.

Those that cannot be removed will need a stereotactic/open needle biopsy.

Recently that there is class I evidence to support this long held belief that aggressive, safe surgical resection is an important favorable prognostic factor, even in the elderly.

STEREOTACTIC BRAIN BIOPSY

- patients who have inoperable tumors
- that a located in critical areas
- confirm histological diagnosis.

r/o other pathology like PCNSL

- additional molecular information
  Determining the status of chromosomes 1p and 19q in anaplastic oligodendroglioma
CRANIOTOMY

- Percutaneous stereotactic biopsy is too risky,
- Patient is symptomatic from mass effect or
- Medically refractory seizures.
- Controversial for decades because of the lack of class I evidence.
- The value of surgery in prolonging survival is controversial, but patients who undergo extensive resection probably have a modest survival advantage.

Biopsy versus resection in the management of malignant gliomas: a systematic review and meta-analysis A review

J Neurosurg 112:1020–1032, 2010

Abraham Tsitlakidis, M.D., M.Sc.,1 Nicolas Foroglou, M.D., Ph.D.,1
Christos A. Venetis, M.D., M.Sc.,2 Ioannis Pat salas, M.D., Ph.D.,1
Athanasios Hatziotiriou, M.D., Ph.D.,3 and Panagiotis Selviaridis, M.D., Ph.D.1

1First Department of Neurosurgery, AHEPA University Hospital; 2Unit for Human Reproduction, First Department of Obstetrics and Gynaecology, Papageorgiou General Hospital, Aristotle University of Thessaloniki; and 3Agios Loukas Clinic, Thessaloniki, Greece
One randomized controlled trial and 4 retrospective studies (involving a total of 1111 patients) were found eligible for this systematic review.

A meta-analysis demonstrated a significant increase in overall survival in the patients treated with resection instead of biopsy (p < 0.0001). However, there did not seem to be any significant difference in progression-free survival between the 2 groups.

Well designed prospective studies are needed for more solid conclusions to be drawn.
RADIATION THERAPY

- Mainstay of treatment increases survival among patients with glioblastomas from a range of 3 to 4 months to a range of 7 to 12 months.

Conventional radiotherapy
- 60 Gy of partial-field external-beam irradiation delivered 5 days per week in fractions of 1.8 to 2.0 Gy.


- **Strategies to increase the radiation dose to the tumor with the use of brachytherapy.**

- **Stereotactic radiosurgery** have failed to improve survival.

Patients older than 70 years of age have a worse prognosis.

Radiotherapy produces a modest benefit in median survival (29.1 weeks) as compared with supportive care (16.9 weeks).

Older patients often tolerate radiotherapy poorly.

An abbreviated course of radiotherapy (40 Gy in 15 fractions over a period of 3 weeks) or chemotherapy with temozolomide (an oral alkylating agent with good penetration of the blood–brain barrier) alone. Outcomes with these approaches are similar to the outcomes with conventional radiotherapy regimens.

CHEMOTHERAPY

- Chemotherapy is assuming an increasingly important role in the treatment.
- Early studies of adjuvant chemotherapy for malignant gliomas with the use nitrosoureas failed to show a benefit.

Two metaanalyses have suggested that adjuvant chemotherapy results in a modest increase in survival (a 6 to 10% increase in the 1-year survival rate).

The European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) conducted a phase III trial comparing radiotherapy alone (60 Gy over a period of 6 weeks) with radiotherapy and concomitant treatment with temozolomide (75 mg per square meter of body-surface area per day for 6 weeks), followed by adjuvant temozolomide therapy (150 to 200 mg per square meter per day for 5 days every 28 days for 6 cycles), in patients with newly diagnosed glioblastomas.
The combination of radiotherapy and temozolomide had an acceptable side-effect profile and, as compared with radiotherapy alone increased the median survival (14.6 months vs. 12.1 months, P<0.001).

In addition, the survival rate at 2 years among the patients who received radiotherapy and temozolomide was significantly greater than the rate among the patients who received radiotherapy alone (26.5% vs. 10.4%).

MGMT

- MGMT is an important repair enzyme that contributes to resistance to temozolomide.
- Patients with glioblastoma and MGMT promoter methylation (45% of the total) who were treated with temozolomide had a median survival of 21.7 months and a 2-year survival rate of 46%.
- In contrast, patients without MGMT promoter methylation who were treated with temozolomide had a significantly shorter median survival of only 12.7 months and a 2-year survival rate of 13.8%.

Currently, temozolomide is used in the treatment of glioblastomas regardless of *MGMT promoter methylation status*.

*However,* if the importance of *MGMT promoter methylation* is confirmed by the results of an ongoing study by the Radiation Therapy Oncology Group (RTOG 0525), patients with unfavorable *MGMT* methylation status may be selected for other treatments in future investigations.
IMPLANTATION OF BIODEGRADABLE POLYMERS CONTAINING Carmustine (GIADER Wafers, MGI PHARMA) INTO THE TUMOR BED AFTER RESECTION OF THE TUMOR.

- Aim of treatment with these polymers is to kill residual tumor cells.
- In a randomized, placebo-controlled trial that investigated the use of these polymers in patients with newly diagnosed malignant gliomas, median survival increased from 11.6 months to 13.9 months (P = 0.03). This survival advantage was maintained at 2 and 3 years.

Therapy for Anaplastic Gliomas

- Anaplastic astrocytomas are treated with radiotherapy and either concurrent and adjuvant temozolomide (as for glioblastomas) or adjuvant temozolomide alone.
ANAPLASTIC OLIGODENDROGLIOMAS AND ANAPLASTIC OLIGOASTROCYTOMAS

- Important subgroup of malignant gliomas that are generally more responsive to therapy than are pure astrocytic tumors.

- Tumors in patients with the 1p and 19q codeletion are particularly sensitive to chemotherapy with PCV — procarbazine, lomustine (CCNU), and vincristine — with response rates of up to 100%, as compared with response rates of 23 to 31% among patients without the deletion of chromosomes 1p and 19q.

Two large phase III studies of PCV chemotherapy with radiotherapy, as compared with radiotherapy alone, in patients with newly diagnosed anaplastic oligodendrogliomas or anaplastic oligoastrocytomas, have been reported.

In both studies, the addition of chemotherapy to radiotherapy increased the time to tumor progression by 10 to 12 month but did not improve overall survival (median, 3.4 and 4.9 years).


MANAGEMENT OF MALIGNANT GLIOMA: PROGRESS IN MULTIMODAL APPROACHES

- Surgery + RT + Chemotherapy
- Surgery + RT
- Surgery
- Conservative Treatment

Weeks of Survival (median)
THERAPY FOR RECURRENT MALIGNANT GLIOMAS

- In patients without medical contraindications
  Surgery
    - can confirm tumor recurrence,
    - reduce intracranial pressure, improve neurological status, and possibly improve efficacy of adjunctive therapy.

Stereotactically guided biopsy procedures allow for
- the sampling of small, inaccessible, or even multiple lesions with minimal patient morbidity and mortality rates (estimated to be 2–5% and 1%, respectively).

Treatment decisions for patients whose imaging studies fail to differentiate between radiation necrosis and tumor recurrence.
In addition to decreasing mass effect, repeated craniotomy allows for the potential in situ delivery of chemotherapy or brachytherapy.

Randomized study Brem, et al evaluating the efficacy of BCNU implantation during repeated resection compared with placebo, reported a 50% improvement in survival at 6 months (56% with BCNU compared with 36% with placebo).

Preoperative performance status and age were significant prognostic factors.

Resection should be seriously considered in those with a high KPS score (70) and whose lesions are in a favorable location.

Rostomily et al., reported a prolonged PFS of 7 weeks in patients undergoing combined chemotherapy plus repeated resection compared with patients receiving chemotherapy alone (21 weeks compared with 14 weeks).

Overall survival rate among this cohort of 51 patients was equivocal.

CHEMOTHERAPY

- Chemotherapy is the most common treatment option for recurrent malignant gliomas.
- Traditionally reserved for salvage treatment of recurrent GBM,
- Administered alone or as a supplement to cytoreductive surgery.
- Chemotherapeutic agents such as TMZ, carboplatin, procarbazine, and imatinib mesylate are currently being examined for their potential in the palliative treatment of recurrent GBMs.
- The value of conventional chemotherapy for recurrent malignant gliomas is modest.
- Chemotherapy is more effective for anaplastic gliomas than for glioblastomas.
- Temozolomide was evaluated in a phase II study involving patients with recurrent anaplastic gliomas previously been treated with nitrosoureas;
- The study showed a 35% response rate. The 6-month rate of progression-free survival was 46%, comparing favorably with the 31% rate of progression-free survival at 6 months for therapies that were reported to be ineffective.

- Temozolomide has only limited activity in patients with recurrent glioblastomas (response rate, 5.4%; 6-month rate of progression-free survival, 21%).
- Other chemotherapeutic agents that are used for recurrent gliomas include nitrosoureas, carboplatin, procarbazine, irinotecan, and etoposide.
- Carmustine wafers have modest activity, increasing the median survival by approximately 8 weeks in patients with recurrent glioblastomas.

NEWER TREATMENT MODALITIES FOR GLIOMA”

- Better understanding of molecular oncogenesis: development of targeted therapies.

- Improvement in the delivery of drugs:
  - Local placement of biodegradable polymers in the resection cavity: ‘Convection enhanced delivery’

- More specifically targeted therapies:
  - Signaling inhibitors as EGF or VEGF receptor inhibitors
  - Gene therapy: attempting to introduce specific genes as p53
INVESTIGATIONAL THERAPIES

Targeted Molecular Therapies
- that target receptor tyrosine kinases such as EGFR, PDGFR, and VEGFR,
- response rates of 0 to 15% and no prolongation of 6-month progression-free survival.
ANTIANGIOGENIC AGENTS

- Older antiangiogenic agents such as thalidomide had only modest activity.
- Newer and more potent angiogenesis inhibitors show promising activity. In preliminary studies, treatment with the combination of bevacizumab and irinotecan was associated with a low incidence of hemorrhage and response rates of 57 to 63% among patients with malignant gliomas.
TARGETS AND POTENTIAL NOVEL THERAPEUTIC AGENTS

- **EGFR** antibodies (including tagged to toxins/radioactive isotopes)
  - tyrosine kinase inhibitors of EGFR (ie. gefitinib, erlotinib)

- **PDGF** inhibitors of tyrosine kinase activity of PDGFR
  - (imatinib)

- **Pl-3 kinase system** small molecules targeting Pl-3 kinase

- **mTOR inhibitors** rapamycin

- **p53** gene therapy

- **Ras pathway inhibitors** antisense oligonucleotides, farnesyl transferase

- **Angiogenesis kinase** antibodies to VEGF, VEGF receptors, tyrosine inhibitors of VEGF
**Clinical Trials of Cotara**

*What is Cotara?*

- Cotara is an experimental new treatment for brain cancer.
- Links a radioactive substance designed for medical uses--->a radioactive isotope--to a targeted monoclonal antibody.
- This monoclonal antibody is designed to target--to bind to--a type of DNA that is exposed only on dead and dying cells.
- Tumors have a significant number of dead and dying cells at their center.
- Cotara’s targeting mechanism enables it to home in on these dying tumor cells and deliver its radioactive “payload” to the center of the tumor.
- Cotara then literally destroys the tumor “from the inside out” by delivering radiation directly to the cells inside the tumor mass.
Patient Eligibility:

- **Any pt with 1st or 2nd recurrence of GBM.**
- Patients who have had prior surgery, chemotherapy, or some forms of radiation treatment may be eligible to participate.
- Excluded if they have received radiosurgery, brachytherapy or other local therapies.
Cotara is delivered through a special method, called convection enhanced delivery (CED).

Uses a catheter to bypass the BBB and target the specific tumor site in the brain.

AIIMS currently one of the centres for Cotara trials
**Cotara® is administered directly into the tumor to increase its safety and tumor-destroying potential.**

SPECT analysis: Cotara can be easily tracked by scanning devices to be sure it is entering the tumor as seen here, and is not dispersing in healthy tissues.
CONCLUSIONS

- Most common primary brain malignancy in adults with very poor prognosis.
- Incurable, but current therapy can prolong survival: surgery + RT + chemotherapy
- Novel agents targeting molecule mechanisms may provide improvements in therapy or may eventual be used for prognostic implications.
Thank you